Major depressive disorder (MDD) is the most common major mental illness, afflicting almost one in five individuals. More than 75% of people who recover from an episode of MDD will have at least one recurrence, with the majority having multiple recurrences. MDD is the leading cause of disability of all medical illnesses, with substantial functional impairment, morbidity, and mortality. [click link for full article]
Popularity: unranked [?]
Related posts:
- Venlafaxine Extended Release Effective For Patients With Major Depression
- FDA Approves Wellbutrin XL(R) (bupropion HCl Extended-release Tablets) For The Prevention Of Seasonal Major Depressive Episodes
- FDA Approves Wellbutrin XL(R) (bupropion HCl Extended-release Tablets) For The Prevention Of Seasonal Major Depressive Episodes
- Osmotica Pharmaceutical Receives FDA Approval To Market Novel Forms Of Extended Release Venlafaxine HCl
- World’s Mental Health Care Needs Not Being Met, Global Survey Finds
Comments
No Responses to “Venlafaxine Extended Release Effective For Patients With Major Depression”